Literature DB >> 30820593

Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.

Sudhir Kumar Yadav1, Devika Soin1, Kouichi Ito1, Suhayl Dhib-Jalbut2.   

Abstract

Dimethyl fumarate (DMF) is an oral, disease-modifying agent for the treatment of relapsing-remitting multiple sclerosis (RRMS). However, details regarding its mode of action are still emerging. It is believed that the mode of action of DMF involves both nuclear factor erythroid-derived 2-related factor (Nrf2)-dependent and independent pathways, which lead to an anti-inflammatory immune response due to type II myeloid cell and Th2 cell differentiation and neuroprotection. In this review, we will focus on the molecular and signaling effects of DMF that lead to changes in peripheral immune cell composition and function, alteration in CNS cell-specific functions, and effect on the blood-brain barrier.

Entities:  

Keywords:  Dimethyl fumarate; Immunomodulation; Neuroprotection; Nuclear factor erythroid-derived 2-related factor; Relapsing–remitting multiple sclerosis

Mesh：

Substances：

Year:  2019        PMID： 30820593     DOI： 10.1007/s00109-019-01761-5

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN： 0946-2716            Impact factor:   4.599


  89 in total

1.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

2.  Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference.

Authors:  U Mrowietz; E Christophers; P Altmeyer
Journal:  Br J Dermatol       Date:  1999-09       Impact factor: 9.302

Review 3.  T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  A Iglesias; J Bauer; T Litzenburger; A Schubart; C Linington
Journal:  Glia       Date:  2001-11       Impact factor: 7.452

4.  Inhibition of dendritic cell differentiation by fumaric acid esters.

Authors:  K Zhu; U Mrowietz
Journal:  J Invest Dermatol       Date:  2001-02       Impact factor: 8.551

5.  Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters.

Authors:  D Werdenberg; R Joshi; S Wolffram; H P Merkle; P Langguth
Journal:  Biopharm Drug Dispos       Date:  2003-09       Impact factor: 1.627

6.  NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger.

Authors:  David Siegel; Daniel L Gustafson; Donna L Dehn; Jin Yi Han; Preecha Boonchoong; Lawrence J Berliner; David Ross
Journal:  Mol Pharmacol       Date:  2004-05       Impact factor: 4.436

7.  Dimethylfumarate is a potent inducer of apoptosis in human T cells.

Authors:  Felix Treumer; Kejian Zhu; Regine Gläser; Ulrich Mrowietz
Journal:  J Invest Dermatol       Date:  2003-12       Impact factor: 8.551

8.  Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I.

Authors:  Einar Martin Aandahl; Walter J Moretto; Patrick A Haslett; Torkel Vang; Tone Bryn; Kjetil Tasken; Douglas F Nixon
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

9.  Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses.

Authors:  Nicolle H R Litjens; Mirjam Rademaker; Bep Ravensbergen; Delphine Rea; Mariena J A van der Plas; Bing Thio; Andrew Walding; Jaap T van Dissel; Peter H Nibbering
Journal:  Eur J Immunol       Date:  2004-02       Impact factor: 5.532

10.  In vitro pharmacokinetics of anti-psoriatic fumaric acid esters.

Authors:  Nicolle H R Litjens; Elisabeth van Strijen; Co van Gulpen; Herman Mattie; Jaap T van Dissel; H Bing Thio; Peter H Nibbering
Journal:  BMC Pharmacol       Date:  2004-10-12
View more
  18 in total

1.  Unraveling the T-B tangle in anti-CD20 multiple sclerosis therapy.

Authors:  Ari Waisman; Anna Ebering
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-02       Impact factor: 11.205

2.  Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis.

Authors:  Vanessa F Moreira Ferreira; Yanqing Liu; Brian C Healy; James M Stankiewicz
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-04-29

Review 3.  Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies.

Authors:  Tyler Ellis Smith; Ilya Kister
Journal:  Curr Neurol Neurosci Rep       Date:  2021-05-19       Impact factor: 5.081

4.  Time to activin on pathogenic T cells.

Authors:  Anna Ebering; Ari Waisman
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-22       Impact factor: 11.205

5.  An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate.

Authors:  Dina Erzina; Alice Capecchi; Sacha Javor; Jean-Louis Reymond
Journal:  Angew Chem Int Ed Engl       Date:  2021-11-05       Impact factor: 16.823

6.  Targeting NRF2 for the Treatment of Friedreich's Ataxia: A Comparison among Drugs.

Authors:  Sara Petrillo; Jessica D'Amico; Piergiorgio La Rosa; Enrico Silvio Bertini; Fiorella Piemonte
Journal:  Int J Mol Sci       Date:  2019-10-21       Impact factor: 5.923

7.  Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19.

Authors:  Cara A Timpani; Emma Rybalka
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-26

8.  Dimethyl fumarate transfer into human milk.

Authors:  Andrea I Ciplea; Palika Datta; Kathleen Rewers-Felkins; Teresa Baker; Ralf Gold; Thomas W Hale; Kerstin Hellwig
Journal:  Ther Adv Neurol Disord       Date:  2020-10-31       Impact factor: 6.570

Review 9.  Pre-clinical and Clinical Implications of "Inside-Out" vs. "Outside-In" Paradigms in Multiple Sclerosis Etiopathogenesis.

Authors:  Haley E Titus; Yanan Chen; Joseph R Podojil; Andrew P Robinson; Roumen Balabanov; Brian Popko; Stephen D Miller
Journal:  Front Cell Neurosci       Date:  2020-10-27       Impact factor: 5.505

10.  Electrophile Signaling and Emerging Immuno- and Neuro-modulatory Electrophilic Pharmaceuticals.

Authors:  Jesse R Poganik; Yimon Aye
Journal:  Front Aging Neurosci       Date:  2020-02-07       Impact factor: 5.750
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.